StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Vikas Sethi, Sethi Finmart

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byVikas Sethi, Sethi FinmartHorizon: Intraday22 Oct 2026, 9:01 am ISTvia Zee Business (Live)

Entry₹1,116Inferred
Target₹1,130
Total upside +1.25%
Stop loss₹1,105-0.99% risk
CMP₹1,110.8Just now
Active-0.47%+1.73%upside left 4h left
Follow Vikas Sethi for new calls(40% target hit, 55 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 16 other Intraday picks this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 10:12 am IST
5 supporting0 opposing
Supports the BUY call (5)

RSI at 30 — oversold territory

Technicals · rsi·22 Oct · today

Zydus Lifesciences' subsidiary Zylidac Bio has partnered with Prolific Machines to scale a biologics manufacturing platform to GMP production.

BSE · Company Update·21 Oct · today

(opens in new tab)

Zydus Lifesciences received USFDA approval for Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

BSE · Company Update·21 Oct · today

(opens in new tab)

Zydus Lifesciences received USFDA approval for its Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

NSE · Press Release·21 Oct · today

(opens in new tab)

Zydus Sunshine Lifesciences has signed an agreement with the Sri Lankan Board of Investment to set up a pharmaceutical manufacturing facility.

BSE · Company Update·15 Oct · 6d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Vikas Sethi, Sethi Finmart

Every call and its outcome